Biotechnology Index

A group of NASDAQ-listed companies designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The NASDAQ Biotechnology Index (BI) is calculated under a modified capitalisation-weighted methodology.

The BI currently includes Affymetrix, Amgen, Applera Corp-Celera Genomics Group, Biogen, Cephalon, Chiron, COR Therapeutics, Genzyme Corporation, Genentech Inc, Gilead Sciences, Human Genome Sciences, IIDEC Pharmaceuticals, Immunex Corporation, Medimmune, Millennium Pharmaceuticals, Protein Design Labs and Vertex Pharmaceuticals.

Mentioned in

index

References in periodicals archive

The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) is up about 10%.

Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma

BIOTECH STOCKS NEAR 2019 LOWS: The iShares Nasdaq Biotechnology Index, an ETF that tracks the stocks of biotech group, is trading relatively unchanged since early January of 2019.

Fly Intel: What to watch in large cap biotech earnings reports

The Nasdaq Biotechnology Index, often used as a barometer for investor sentiment about drug prices, was up 0.1 percent after rising as much as 0.5 percent earlier.

Trump attacks Pfizer over drug prices in latest dig at industry-BYLN- By Drew Armstrong Bloomberg

The SandP healthcare index ended 1.47 percent higher, while the Nasdaq Biotechnology index rallied 2.68 percent.

Market - World Stock Markets

M2 PHARMA-December 19, 2017-GlycoMimetics to Join NASDAQ Biotechnology Index

GlycoMimetics to Join NASDAQ Biotechnology Index

The Nasdaq Biotechnology Index is up 29% since the start of the year, and outpacing other indices.

FDA's Drug Approvals on Track to Double Over Last Year's Pace

Even with the recent downturn, the NASDAQ Biotechnology Index (IBB) has increased 250% in the past five years.

The new life science financing landscape: raise funds outside of traditional venture capital

The Nasdaq Biotechnology Index slipped 2.2 percent, paring its best quarterly gain since 2013.

Stocks trim 1Q gain; Dow loses 200

After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the NASDAQ Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.

Has the biotech bubble burst?